Targeting angiogenesis in chronic liver diseases with portal hypertension: anti-placenta growth factor inhibitor or multikinase inhibitor sorafenib?

摘要

We read with great interest the article by Van Steenkiste et al. that reported the benefits of placenta growth factor (PlGF) inhibition on portal hypertension in mice. The authors suggest that PlGF inhibitors could be useful for the treatment with chronic liver diseases. They emphasize the good safety profile of PlGF inhibitors, compared to the risk of bleeding associated with the use of anti-vascular endothelial growth factor (VEGF) agents such as sorafenib.